IRONMATT RESEARCH GRANTS
Since 2007, our Board of Directors has worked to fulfill the IronMatt mission to financially support families living with pediatric brain tumors and to fund research in the hopes of finding a cure.
The Grant Program, driven by top physicians on our Medical Advisory Committee, continues to review groundbreaking project proposals from cancer researchers around the country.
As of 2022, IronMatt has granted nearly $6 million, funding 69 important research projects at institutions across the U.S. and Canada.
Apply for a 2022-23 IronMatt Research Grant
Letter of Intent Due November 13, 2022
$975,000 to Research in 2022!
$75,000 Matthew Larson Research Grant Recipients
Mariella Filbin
Dana-Faber Cancer Institute
Boston, MA
Kelsey Bertrand
St. Jude's Children's Research Hospital
Memphis, TN
Vijay Ramaswany
Hospital for Sick Children
Washington, DC
Nicholas Vitanza
Seattle Children's Hospital
Seattle, WA
$100,000 Grants Funded for a Third Consecutive Year
Thomas De Raedt
Children's Hospital of Philadelphia
Philadelphia, PA
Sameer Farouk Sait
Memorial Sloan Kettering Cancer Center
New York, NY
Patrick Pirrotte
Translational Genomics Research Institute
Phoenix, AZ
Brian Na
University of California at Los Angeles
Los Angeles, CA
Nicholas Whipple
University of Utah School of Medicine
Salt Lake City, UT
Yanxin Pei
Children's National Hospital
Washington, DC
Michael Taylor
The Hospital for Sick Children
Toronto, Canada
Alexandra Miller
Memorial Sloan Kettering Cancer Center
New York, NY
IronMatt acknowledged by grant recipient, Dr. Javad Nazarian, in his recently published
Nuero-Oncology article on children diagnosed with
Diffuse Midline Gliomas
IronMatt acknowledged for funding groundbreaking results in clinical trials.
Mark Souweidane, MAC member and Zhiping Zhou, former grant recipient
Treatment of DIPG - Lancet Oncology - June 2018
Samuel Cheshier, former grant recipient
Treatment of Medulloblastoma - Nature Communications - October 2018
Medical Advisory Committee
Previous Grant Recipients
recipient Michelle Monje,
from Stanford University,
is making advances in the treatment of
High-grade glioma tumors.